OptimizeRx (NASDAQ:OPRX) Stock Rating Lowered by ValuEngine

ValuEngine cut shares of OptimizeRx (NASDAQ:OPRX) from a strong-buy rating to a buy rating in a report published on Saturday, ValuEngine reports.

Other equities analysts have also issued reports about the stock. B. Riley lowered their price target on shares of OptimizeRx from $21.00 to $20.00 and set a buy rating on the stock in a research report on Monday, December 30th. TheStreet lowered shares of OptimizeRx from a c rating to a d+ rating in a research report on Wednesday, November 20th. William Blair initiated coverage on shares of OptimizeRx in a research report on Friday, January 3rd. They set an outperform rating on the stock. Finally, Zacks Investment Research lowered shares of OptimizeRx from a hold rating to a sell rating in a research report on Tuesday, November 5th. One investment analyst has rated the stock with a sell rating and three have assigned a buy rating to the stock. The company presently has an average rating of Buy and an average price target of $18.00.

OPRX opened at $10.91 on Friday. The firm has a market capitalization of $149.78 million, a PE ratio of -121.22, a PEG ratio of 5.84 and a beta of 0.39. OptimizeRx has a twelve month low of $8.63 and a twelve month high of $17.24. The firm’s 50-day moving average price is $10.09 and its 200 day moving average price is $13.01. The company has a current ratio of 7.00, a quick ratio of 7.00 and a debt-to-equity ratio of 0.01.

OptimizeRx (NASDAQ:OPRX) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.15). The business had revenue of $5.00 million for the quarter, compared to analyst estimates of $7.21 million. OptimizeRx had a negative return on equity of 3.68% and a negative net margin of 5.32%. As a group, analysts predict that OptimizeRx will post -0.06 earnings per share for the current fiscal year.

In other news, CEO William J. Febbo bought 5,000 shares of the firm’s stock in a transaction on Wednesday, November 6th. The shares were bought at an average cost of $10.38 per share, for a total transaction of $51,900.00. Insiders own 8.40% of the company’s stock.

A number of large investors have recently bought and sold shares of OPRX. Wells Fargo & Company MN boosted its holdings in OptimizeRx by 9.5% in the 2nd quarter. Wells Fargo & Company MN now owns 13,562 shares of the company’s stock valued at $219,000 after purchasing an additional 1,180 shares during the last quarter. Charles Schwab Investment Management Inc. acquired a new position in shares of OptimizeRx in the 2nd quarter worth approximately $454,000. Bank of New York Mellon Corp acquired a new position in shares of OptimizeRx in the 2nd quarter worth approximately $488,000. Renaissance Technologies LLC acquired a new position in shares of OptimizeRx in the 2nd quarter worth approximately $520,000. Finally, Northern Trust Corp lifted its holdings in shares of OptimizeRx by 128.9% in the 2nd quarter. Northern Trust Corp now owns 46,656 shares of the company’s stock worth $756,000 after acquiring an additional 26,274 shares during the last quarter. Institutional investors own 59.59% of the company’s stock.

OptimizeRx Company Profile

OptimizeRx Corporation provides digital health messaging services for pharmaceutical companies to communicate with healthcare providers. The company's cloud-based solutions support patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and critical clinical information; and network consists of electronic health records platforms, which provide the ambulatory patient market with access to their workflow at the point-of-care.

Featured Article: What is a back-end load?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.